Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Jan 11, 2021 12:36pm
226 Views
Post# 32267594

Wainwright BioConnect 2021 Virtual Conference

Wainwright BioConnect 2021 Virtual Conference

CRDL participated in this virtual conference, I have attached the link to view it, it's just under 22 minutes.

Overall a good presentation from Elsley, I didn't learn anything new from it however if you are new to CRDL, I think it would be beneficial to view it.

The SP needs a catalyst to move it forward, I don't see anything on the horizon to do this; likely the first one will be the sales at Shoppers which would likely be in March or April. We could also see something on agreements in other areas like Europe and Latin America. I can't see anything happening on the NASDAQ listing until CRDL is north of $5.00 as you need a $4.00 US SP minimum to list.

https://bit.ly/3qdFgFl

<< Previous
Bullboard Posts
Next >>